Filing Flows › Vir Biotechnology (VIR) › Q2 2026 › vs Q2 2025
Vir Biotechnology (VIR) Q2 2026 vs Q2 2025 (year over year)
Vir Biotechnology's revenue rose $238M (197×) from $1.2M in Q2 2025 to $239M in Q2 2026. The biggest changes: License and collaboration revenue +$239M (—); Grant revenue −$172K (-94%).
Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%, net earnings $80.1M, operating cash flow $123M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| License and collaboration revenue | $239M | −$495K | $239M | — |
| Grant revenue | $11K | $183K | −$172K | -94% |
| Revenue | $239M | $1.2M | $238M | 197× |
| Other income, net | $6.8M | $7.6M | −$837K | -11% |
| Operating profit | $73.5M | −$118M | $192M | — |
| Costs & expenses | $165M | $120M | $45.8M | +38% |
| Pre-tax earnings | $80.3M | −$111M | $191M | — |
| Research & development | $135M | $97.5M | $37.8M | +39% |
| SG&A | $30.2M | $22.3M | $7.9M | +36% |
| Net earnings | $80.1M | −$111M | $191M | — |
| Income tax | $179K | $170K | $9K | +5% |
| Depreciation & amortization | $2.8M | $2.9M | −$115K | -4% |
| Share-based compensation | $12.4M | $12.5M | −$60K | -0.5% |
| Working capital & other | $28.1M | −$24.6M | $52.7M | — |
| Operating cash flow | $123M | −$120M | $244M | — |
| Free cash flow (OCF − capex) | $123M | −$123M | $246M | — |
| Capital expenditures | $32K | $2.5M | −$2.5M | -99% |
Questions
How much did Vir Biotechnology's revenue grow year over year in Q2 2026?
Vir Biotechnology's revenue rose $238M (197×) from $1.2M in Q2 2025 to $239M in Q2 2026.
What drove Vir Biotechnology's revenue change in Q2 2026?
License and collaboration revenue +$239M (—); Grant revenue −$172K (-94%).